Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Gains from Sales and Divestitures (2016 - 2019)

Akebia Therapeutics (AKBA) has disclosed Gains from Sales and Divestitures for 3 consecutive years, with $323136.0 as the latest value for Q4 2019.

  • On a quarterly basis, Gains from Sales and Divestitures fell 60.52% to $323136.0 in Q4 2019 year-over-year; TTM through Dec 2019 was $323136.0, a 60.52% decrease, with the full-year FY2019 number at $323136.0, down 60.52% from a year prior.
  • Gains from Sales and Divestitures was $323136.0 for Q4 2019 at Akebia Therapeutics, down from $818395.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $818395.0 in Q4 2018 to a low of $26000.0 in Q4 2017.
  • A 3-year average of $389177.0 and a median of $323136.0 in 2019 define the central range for Gains from Sales and Divestitures.
  • Peak YoY movement for Gains from Sales and Divestitures: surged 3047.67% in 2018, then crashed 60.52% in 2019.
  • Akebia Therapeutics' Gains from Sales and Divestitures stood at $26000.0 in 2017, then soared by 3047.67% to $818395.0 in 2018, then tumbled by 60.52% to $323136.0 in 2019.
  • Per Business Quant, the three most recent readings for AKBA's Gains from Sales and Divestitures are $323136.0 (Q4 2019), $818395.0 (Q4 2018), and $26000.0 (Q4 2017).